• Daruwalla C, …. Coles AJ, Kalincik T, Brown JWL. Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis. Mult Scler. 2023 Feb 27:13524585231151951. doi: 10.1177/13524585231151951. Epub ahead of print. PMID: 36851894.
• Brittain G, Coles AJ, Giovannoni G, Muraro PA, Palace J, Petrie J, Roldan E, Scolding NJ, Snowden JA, Sharrack B. Autologous haematopoietic stem cell transplantation for immune-mediated neurological diseases: what, how, who and why? Pract Neurol. 2022 Sep 26:pn-2022-003531. doi: 10.1136/pn-2022-003531. Epub ahead of print. PMID: 36162855.
• Brown JWL, Prados F, Altmann DR, Kanber B, Stutters J, Cunniffe NG, Jones JL, Georgieva ZG, Needham EJ, Daruwalla C, Wheeler-Kingshott CG, Connick P, Chandran S, Franklin R, MacManus D, Samson R, Coles A, Chard D. Remyelination varies between and within lesions in multiple sclerosis following bexarotene. Ann Clin Transl Neurol. 2022 Oct;9(10):1626-1642. doi: 10.1002/acn3.51662. Epub 2022 Sep 17. PMID: 36116011; PMCID: PMC9539389.
• Needham EJ, …. Coles AJ, Menon DK; Cambridge NeuroCOVID Group; CITIID-NIHR COVID-19 BioResource Collaboration; Cambridge NIHR Clinical Research Facility. Brain injury in COVID-19 is associated with dysregulated innate and adaptive immune responses. Brain. 2022 Nov 21;145(11):4097-4107. doi: 10.1093/brain/awac321. PMID: 36065116; PMCID: PMC9494359.
• Hill MFE, Cunniffe NG, Franklin RJM. Seeing is believing: Identifying remyelination in the central nervous system. Curr Opin Pharmacol. 2022 Oct;66:102269. doi: 10.1016/j.coph.2022.102269. Epub 2022 Aug 1. PMID: 35926475.
• McMurran CE, Mukherjee T, Brown JWL, Michell AW, Chard DT, Franklin RJM, Coles AJ, Cunniffe NG. Remyelination in humans due to a retinoid-X receptor agonist is age-dependent. Ann Clin Transl Neurol. 2022 Jul;9(7):1090-1094. doi: 10.1002/acn3.51595. Epub 2022 May 19. PMID: 35587315; PMCID: PMC9268872.
• Coles AJ, Jones JL, Vermersch P, Traboulsee A, Bass AD, Boster A, Chan A, Comi G, Fernández Ó, Giovannoni G, Kubala Havrdova E, LaGanke C, Montalban X, Oreja-Guevara C, Piehl F, Wiendl H, Ziemssen T.Mult Scl Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data. Mult Scler. 2022 Apr;28(5):842-846. doi: 10.1177/13524585211061335. Epub 2021 Dec 9. PMID: 34882037; PMCID: PMC8978465.
• Georgieva ZG, Dӧffinger R, Kumararatne D, Coles AJ, McCarthy C. Diminished seroconversion following a single SARS-COV-2 vaccine in ocrelizumab-treated relapsing-remitting multiple sclerosis patients. Mult Scler. 2022 Jun;28(7):1126-1130. doi: 10.1177/13524585211046786. Epub 2021 Oct 1. PMID: 34595965; PMCID: PMC9131405.
• Gaunt CM, Rainbow DB, Mackenzie RJ, Jarvis LB, Mousa HS, Cunniffe N, Georgieva Z, Brown JW, Coles AJ, Jones JL. The MS Remyelinating Drug Bexarotene (an RXR Agonist) Promotes Induction of Human Tregs and Suppresses Th17 Differentiation n Vitro. Front Immunol. 2021 Aug 10;12:712241. doi: 10.3389/fimmu.2021.712241. PMID: 34447379; PMCID: PMC8382874.
• Brown JWL, Cunniffe NG, Prados F, Kanber B, Jones JL, Needham E, Georgieva Z, Rog D, Pearson OR, Overell J, MacManus D, Samson RS, Stutters J, Ffrench-Constant C, Gandini Wheeler-Kingshott CAM, Moran C, Flynn PD, Michell AW, Franklin RJM, Chandran S, Altmann DR, Chard DT, Connick P, Coles AJ. Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study. Lancet Neurol. 2021 Sep;20(9):709-720. doi: 10.1016/S1474-4422(21)00179-4. PMID: 34418398.